Stock Track | Verona Pharma Soars on Strong Ohtuvayre Launch and Q3 Revenue Beat

Stock Track11-04

Shares of Verona Pharma plc (NASDAQ: VRNA) surged over 8% in pre-market trading on Monday, following the company's impressive third-quarter 2024 financial results and updates on the successful launch of its COPD drug Ohtuvayre (ensifentrine).

For the quarter ended September 30, 2024, Verona Pharma reported net sales of $5.6 million, significantly beating analyst estimates of $2 million. This strong revenue performance was driven by the initial launch of Ohtuvayre, which received FDA approval in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

According to the company's press release, Ohtuvayre recorded over 5,000 prescriptions filled and was prescribed by more than 2,200 unique healthcare professionals across a broad COPD patient population in just the first 12 weeks of launch. Verona Pharma noted that net sales in October exceeded the third quarter, indicating continued acceleration in demand for the novel COPD therapy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145812505?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145812505","market":"us","top_or_hot":-1,"title":"Stock Track | Verona Pharma Soars on Strong Ohtuvayre Launch and Q3 Revenue Beat","media":"Stock Track","content":"<p>Shares of Verona Pharma plc (NASDAQ: VRNA) surged over 8% in pre-market trading on Monday, following the company's impressive third-quarter 2024 financial results and updates on the successful launch of its COPD drug Ohtuvayre (ensifentrine).</p>\n\n<p>For the quarter ended September 30, 2024, Verona Pharma reported net sales of $5.6 million, significantly beating analyst estimates of $2 million. This strong revenue performance was driven by the initial launch of Ohtuvayre, which received FDA approval in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD).</p>\n\n<p>According to the company's press release, Ohtuvayre recorded over 5,000 prescriptions filled and was prescribed by more than 2,200 unique healthcare professionals across a broad COPD patient population in just the first 12 weeks of launch. Verona Pharma noted that net sales in October exceeded the third quarter, indicating continued acceleration in demand for the novel COPD therapy.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Verona Pharma Soars on Strong Ohtuvayre Launch and Q3 Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Verona Pharma Soars on Strong Ohtuvayre Launch and Q3 Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-04 18:22 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Verona Pharma plc (NASDAQ: VRNA) surged over 8% in pre-market trading on Monday, following the company's impressive third-quarter 2024 financial results and updates on the successful launch ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRNA","symbol_name":"维罗纳制药","start_time":0,"source_url":"","article_id":"1145812505","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145812505","pubTimestamp":1730715743,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Verona Pharma plc  surged over 8% in pre-market trading on Monday, following the company's impressive third-quarter 2024 financial results and updates on the successful launch of its COPD drug Ohtuvayre .For the quarter ended September 30, 2024, Verona Pharma reported net sales of $5.6 million, significantly beating analyst estimates of $2 million. This strong revenue performance was driven by the initial launch of Ohtuvayre, which received FDA approval in June 2024 for the maintenance","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRNA":"维罗纳制药"},"translate_title":"股票赛道Verona Pharma因Ohtuvayre的强劲推出和第三季度收入超出预期而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRNA":1},"content_text":"Shares of Verona Pharma plc (NASDAQ: VRNA) surged over 8% in pre-market trading on Monday, following the company's impressive third-quarter 2024 financial results and updates on the successful launch of its COPD drug Ohtuvayre (ensifentrine).\nFor the quarter ended September 30, 2024, Verona Pharma reported net sales of $5.6 million, significantly beating analyst estimates of $2 million. This strong revenue performance was driven by the initial launch of Ohtuvayre, which received FDA approval in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD).\nAccording to the company's press release, Ohtuvayre recorded over 5,000 prescriptions filled and was prescribed by more than 2,200 unique healthcare professionals across a broad COPD patient population in just the first 12 weeks of launch. Verona Pharma noted that net sales in October exceeded the third quarter, indicating continued acceleration in demand for the novel COPD therapy.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145812505"}